Active, not recruitingPhase 3NCT05409066
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma
Studying Follicular lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Genmab
- Principal Investigator
- ABBVIE INC.AbbVie
- Intervention
- Epcoritamab(drug)
- Enrollment
- 549 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2029
Study locations (30)
- The University of Arizona Cancer Center - North Campus /ID# 228862, Tucson, Arizona, United States
- University of Arkansas for Medical Sciences /ID# 227198, Little Rock, Arkansas, United States
- Alta Bates Summit Medical Center for Research /ID# 229428, Berkeley, California, United States
- Beverly Hills Cancer Center /ID# 231535, Beverly Hills, California, United States
- Long Beach Memorial Medical Ct /ID# 228997, Long Beach, California, United States
- University of Southern California /ID# 227195, Los Angeles, California, United States
- Valkyrie Clinical Trials /ID# 268502, Los Angeles, California, United States
- Duplicate_Emory University /ID# 227299, Atlanta, Georgia, United States
- Hawaii Cancer Care - Waterfront Plaza /ID# 262448, Honolulu, Hawaii, United States
- Northwestern University Feinberg School of Medicine /ID# 227248, Chicago, Illinois, United States
- Goshen Center for Cancer Care /ID# 227189, Goshen, Indiana, United States
- Community Health Network, Inc. /ID# 259756, Indianapolis, Indiana, United States
- Our Lady Of The Lake Regional Medical Center /ID# 251393, Baton Rouge, Louisiana, United States
- University of Maryland, Baltimore /ID# 227191, Baltimore, Maryland, United States
- Massachusetts General Hospital /ID# 245233, Boston, Massachusetts, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
AbbVie
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05409066 on ClinicalTrials.govOther trials for Follicular lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07546760A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234AstraZeneca
- RECRUITINGNCT07528781Novel 3-dimensional Echocardiographic Quantification of Mitral Regurgitant VolumeGermans Trias i Pujol Hospital
- RECRUITINGPHASE2NCT07029503Swedish Cardiac And Renal Failure Study-1Karolinska Institutet
- RECRUITINGNCT07154823A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic MalignanciesTempus AI
- RECRUITINGNCT07328035Remission in Adults With Severe Asthma in ThailandThammasat University
- RECRUITINGPHASE3NCT07083154GLP-1/GCG Dual Agonist in Type 2 Diabetes With Early Dementia (LIGHT-COG Study)The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- RECRUITINGPHASE2NCT07128641Odronextamab in Low Tumor Volume Advanced FLGottfried von Keudell, MD PhD
- RECRUITINGPHASE3NCT06911502A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)Celgene